ArticleNeuropsychiatric disease and treatment2025
Comprehensive Analysis of the Microbiome and Metabolome: Unveiling Interactions Between Intestinal Flora and Metabolites in Schizophrenia.
Article in Neuropsychiatric disease and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Gut Microbiota in Schizophrenia: Taxonomic Shifts, Beta- Diversity Alterations, and Biomarker Potential: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Gut Microbiome Dysregulation Across Schizophrenia Spectrum Disorders: Bacteria-, Fungi- and Virome-Level Alterations with Molecular and Immunological Implications.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Schizophrenia (SZ) is a complex, multifactorial neurodevelopmental disorder characterized as a severe mental illness. Despite extensive research, its etiology and pathogenesis remain largely elusive. Recent studies suggest that the intestinal microbiota and its metabolites may play critical roles in the onset and regulation of SZ. This study aims to examine the characteristics of the intestinal microbiota and metabolomics in patients with SZ and to explore their correlation with clinical symptoms. Methods: This study involved thirty-five patients diagnosed with schizophrenia (SZ group) and thirty healthy control participants (HC group). Fecal samples were collected and analyzed using microbiome (16S rRNA gene sequencing) and metabolome (UPLC-MS) techniques. Bioinformatics and statistical analyses were conducted to interpret the data. Results: Age, sex, and BMI were comparable between the SZ and HC groups. Microbial diversity sequencing identified 837 operational taxonomic units (OTUs) across both groups. Although alpha diversity metrics showed no significant difference, beta diversity metrics revealed notable disparities. At the genus level, differences were observed in nine bacterial groups: Conclusion: The study reveals significant abnormalities in the intestinal flora and metabolites of SZ patients, correlating with clinical severity. These findings offer new insights into the interactions between the gut microbiome and metabolites, potentially contributing to the understanding of the pathophysiology of schizophrenia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.